ANNX — Annexon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1528115 ·
Last close
$3.47
Market Cap
$661.95M
52W High
$7.18
52W Low
$2.99
ADV30
3,551,316
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -52,238,000 | -51,218,000 | 250,408,000 | 102,389,000 | 107,613,000 |
| Jun 2026 | 0 | — | -57,227,000 | -55,348,000 | 246,068,000 | 199,270,000 | 60,007,000 |
| Mar 2026 | 0 | — | -46,053,000 | -44,142,000 | 262,888,000 | 175,208,000 | 58,355,000 |
| Dec 2025 | 0 | — | -50,258,000 | -48,256,000 | 277,571,000 | 162,051,000 | 65,923,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-189,409,000
Investing CF
$-59,996,000
Financing CF
$212,374,000
CapEx
$-137,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,068,097,000
Inventory
—
Receivables
—
ST Investments
$110,985,000
EBIT TTM
$-203,923,000
Pretax Income TTM
$-198,964,000
Interest Exp TTM
$833,000
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -216,407,000 | -206,690,000 | 277,571,000 | 65,923,000 | 211,648,000 | -186,356,000 |
| Dec 2024 | 0 | -154,073,000 | -138,200,000 | 350,071,000 | 56,966,000 | 293,105,000 | -118,006,000 |
| Dec 2023 | 0 | -143,723,000 | -134,237,000 | 297,674,000 | 47,118,000 | 250,556,000 | -121,142,000 |
| Dec 2022 | 0 | -145,599,000 | -141,947,000 | 285,096,000 | 53,902,000 | 231,194,000 | -116,309,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-202,668,000
OpCashFlow TTM
—
Assets (Latest)
$246,068,000
Forward EPS
$-1.10
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $3.52 · call oi: 21,257 · put oi: 6,908
Expected Move to 2026-12-18:
±$2.45
(69.60%) —
implied range
$1.07 –
$5.97
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | $660.27M | $19.20 | — |
| JANX | Janux Therapeutics, Inc. | $655.27M | $10.71 | — |
| GERN | GERON CORP | $644.24M | $1.00 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
News headlines (Yahoo Finance, 1h cache)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-11-17 21:01 · Yahoo
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
2026-11-09 21:01 · Yahoo
Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug
2026-11-04 10:14 · Yahoo
Annexon to Participate in Upcoming September Investor Conferences
2026-09-02 12:00 · Yahoo
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
2026-08-24 08:08 · Yahoo
Annexon (ANNX), What Is Behind Its Latest Update?
2026-08-13 18:13 · Yahoo
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
2026-08-12 11:33 · Yahoo
Wells Fargo Names Top Pick in Biotechnology Sector
2026-11-11 16:24 · Yahoo
Annexon, Inc. Q2 2026 Earnings Call Summary
2026-08-12 20:56 · Yahoo
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
2026-10-28 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.